SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

Paris, May 11, 2021 – SparingVision (or the 'Company'), a genomic medicine company developing vision saving treatments for ocular diseases, is pleased to announce that it will present a poster highlighting the Company's recent research into ocular diseases and its lead gene therapy treatment, SPVN06, at the American Society of Gene and Cell Therapy ('ASGCT') 24th Annual Meeting. Details of the poster can be found below.

Poster: *Rod-Derived Cone Viability Factor Provides Trophic Support for Cone Photoreceptors in a Pig Model of Retinitis Pigmentosa (Abstract #552)*

SparingVision administered SPVN06 via subretinal injection in pigs in their first postnatal week and evaluated its effects on cone morphology, Dr Jennifer Noel, from the University of Louisville will present the poster on Tuesday 11 May 2021 from 08:00 AM to 10:00 AM EST. The administration of the AAV SPVN06 therapy was found to preserve cone morphology as well as preserve m-opsin expression in cone segments. It also leads to a greater expression of rod-derived cone viability factor ('RdCVFL').

The abstract of the presentation is available on the ASGCT website.

****ENDS****

Contacts:

SparingVision

Stéphane Boissel — President and CEO

Nathalie Trepo — Investor Relations

nathalie.trepo@sparingvision.com

Consilium Strategic Communications

Amber Fennell, Davide Salvi, Priit Piip

+44 (0)20 3709 5700

sparingvision@consilium-comms.com

NOTES TO EDITORS:

About SparingVision:

SPARINGVISION
GENOMIC MEDICINE IN OPHTHALMOLOGY

SparingVision is a genomic medicines company, translating pioneering science into vision saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is SPVN06, a gene independent treatment for retinitis pigmentosa (RP), the most common inherited retinal disease affecting two million people worldwide. SPVN06 could form the basis of a suite of new sight saving treatments as it could be applicable to many other retinal diseases, regardless of genetic cause.

The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.

About SPVN06:

SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors, which inevitably leads to blindness in patients with rod-cone dystrophies (RCD). SparingVision's primary disease target is Retinitis Pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved to treat RP patients independently of their genetic background. This approach is potentially applicable to many more diseases where the loss of rods is known to be an early signal of the disease. First-in-man trials, with SPVN06 in patients with RP, will be commencing in H2 2021.